Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose 5% provides a source of calories and water for hydration, correcting hypoglycemia by increasing blood glucose levels. Sodium chloride 0.45% and potassium chloride 5 m Eq restore electrolyte balance: sodium and chloride are essential for maintenance of extracellular fluid volume and acid-base balance; potassium is critical for neuromuscular function, cardiac contractility, and intracellular osmotic pressure.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Fluid and electrolyte replacement,Treatment of hypokalemia,Correction of metabolic acidosis (as part of balanced solution),Maintenance hydration with minimal caloric supplementation,Off-label: Prevention of ketosis in fasting or catabolic states
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Intravenous infusion at a rate determined by fluid and electrolyte requirements; typical adult dose is 1000-2000 m L over 24 hours, not exceeding 50 m L/kg/day.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Dextrose: ~1.5-2.5 minutes (rapid cellular uptake). Sodium/potassium: hours to days (depends on total body stores and renal function); in renal failure, half-life is prolonged.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Dextrose is metabolized via glycolysis and oxidative phosphorylation; excess glucose converted to glycogen or fat. Potassium and sodium are not metabolized but excreted renally; chloride is excreted renally or in sweat.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Renal: Dextrose is metabolized to CO2 and water, not excreted unchanged; sodium and potassium are primarily excreted renally (>90% of load), with minor fecal loss (<5%).
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Dextrose: negligible. Sodium/potassium: not protein-bound.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
Dextrose: ~0.2 L/kg (extracellular fluid). Sodium/potassium: Vd approximates total body water (0.6 L/kg) for potassium; sodium Vd ~0.2 L/kg (extracellular).
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Intravenous: 100% (only route used). Not administered orally for this purpose.
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
GFR > 50 m L/min: no adjustment. GFR 10-50 m L/min: reduce dose by 50% or adjust potassium content based on serum levels. GFR < 10 m L/min: avoid use or use with extreme caution; monitor potassium closely; may require potassium restriction.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
Child-Pugh A: no adjustment. Child-Pugh B: monitor potassium levels; reduce potassium content if hyperkalemia risk. Child-Pugh C: avoid potassium-containing solutions unless severe hypokalemia; monitor serum potassium closely.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Intravenous infusion at 5-10 m L/kg/hour initially, adjusted based on serum electrolytes and fluid status; maximum 50 m L/kg/day; potassium component requires weight-based dosing: 0.5-1 m Eq/kg/day for maintenance, not to exceed 3 m Eq/kg/day.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Elderly patients: use lower initial infusion rates (e.g., 50-100 m L/hour) and titrate based on renal function and cardiac status; monitor for fluid overload and electrolyte imbalances; reduce potassium content if renal impairment present.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
None
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Monitor serum potassium, glucose, and fluid balance closely; avoid in patients with severe renal impairment or oliguria; risk of hyperkalemia with rapid infusion in renal dysfunction; contains aluminum (may accumulate with prolonged use); use with caution in heart failure, pulmonary edema, or hyperosmolar states.
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hyperkalemia, hypernatremia, severe renal impairment with oliguria, anuria, or impaired potassium excretion; clinically significant fluid overload; hypersensitivity to any component; patients with sickle cell disease (risk of thrombosis).
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
Avoid high-potassium foods (e.g., bananas, oranges, potatoes, spinach) and salt substitutes containing potassium chloride to prevent hyperkalemia. No other food interactions.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
No known teratogenic risk. Dextrose, sodium chloride, and potassium chloride are normal blood constituents. At clinically relevant doses, no fetal harm is expected in any trimester.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Safe during breastfeeding. Components are normal plasma constituents and enter breast milk in negligible amounts. M/P ratio not applicable.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
No specific dose adjustment required for pregnancy. Monitor for gestational diabetes or preeclampsia; adjust infusion rate to avoid fluid overload or electrolyte imbalances. Consider increased volume of distribution and glomerular filtration rate in pregnancy only if clinically significant.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Restricted in patients with hyperkalemia, severe renal impairment, or oliguria. Use with caution in heart failure, pulmonary edema, or conditions with sodium retention. Monitor serum potassium, renal function, and fluid balance. Contains 5.5 m Eq/L potassium; rate must not exceed 10-20 m Eq/h via peripheral line to avoid phlebitis and cardiac effects.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
This solution provides fluids, sugar, and potassium to correct dehydration and electrolyte imbalances.,Report any signs of fluid overload (swelling, shortness of breath), hyperkalemia (muscle weakness, palpitations), or infusion site reactions.,Do not consume additional potassium supplements or salt substitutes without consulting your doctor.,Tell your healthcare provider if you have kidney disease, heart problems, or are on a potassium-restricted diet.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose 5% provides a source of calories and water for hydration, correcting hypoglycemia by increasing blood glucose levels. Sodium chloride 0.45% and potassium chloride 5 m Eq restore electrolyte balance: sodium and chloride are essential for maintenance of extracellular fluid volume and acid-base balance; potassium is critical for neuromuscular function, cardiac contractility, and intracellular osmotic pressure.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER is: Intravenous infusion at a rate determined by fluid and electrolyte requirements; typical adult dose is 1000-2000 m L over 24 hours, not exceeding 50 m L/kg/day.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER is classified as Category A/B. No known teratogenic risk. Dextrose, sodium chloride, and potassium chloride are normal blood constituents. At clinically relevant doses, no fetal harm is expected in any trimester. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.